Brant Biehn is the Senior VP Commercial Operations at Vaxart Biosciences. He is responsible for Business Development and Commercial Readiness for the organization.
Prior to joining Vaxart, Mr. Biehn served as a consultant, where his role included business development, investor relations, and general management for a variety of pharmaceutical and medical device companies. Earlier, he served as chief commercial officer at Dynavax Technologies Corporation, where he helped raised significant capital and was responsible for the development and execution of Dynavax’s commercial strategy, including global sales, marketing and supply chain management, leading a team of 70 professionals preparing to launch Heplisav®.
Before Dynavax, Mr. Biehn held sales and marketing positions of increasing seniority at Merck, culminating in the position of Global Brand Leader with global responsibility for the manufacturing, commercial, clinical and regulatory activities for vaccines such as ZOSTAVAX®, PNEUMOVAX®, RECOMBIVAX HB® and VAQTA®.
Mr Biehn has a B.Sc. in Computer Science from Memorial University of Newfoundland.